NIH Funds Human Tissue Models for Infection Research
The program seeks 7 to 11 awards in FY 2028 to refine human cell-based systems toward regulatory use, replacing some animal-based testing.
Updated on Nov. 3, 2026 in Life Sciences

The National Institutes of Health has issued a funding opportunity, RFA-AI-28-012, to establish Translational Centers that use human cell-based microphysiological systems to study infectious diseases. The development is a funding announcement, not a shipped technology; NIH anticipates funding roughly 7 to 11 awards in FY 2028.
Why it matters
The program reflects recent NIH and Food and Drug Administration initiatives in new approach methodologies, which aim to better reflect human biology while reducing reliance on animal studies. It signals a push to qualify human tissue models to a standard consistent with regulatory use.
The funding opportunity specifies a maximum project period of 5 years and a consortium structure with an Administrative Core, a Qualification Core, one or more Scientific Cores, and multiple Research Projects. It requires human-derived microphysiological system platforms and demonstrated technical reproducibility. Performance benchmarks for the models are not stated in the source.
The players
National Institutes of Health (NIH)
The U.S. federal biomedical research agency that issued the funding opportunity and funds research through cooperative agreements across infectious-disease and translational science.
Food and Drug Administration (FDA)
The U.S. regulator whose recent new approach methodologies initiative encourages human-based testing alternatives to animal studies in drug and device evaluation.
The details
Microphysiological systems are engineered platforms that grow human cells into miniature tissue models meant to mimic organ function outside the body. Under this funding opportunity, each Translational Center will combine administrative oversight, a qualification core that validates the models, scientific cores for specialized research, and several individual research projects. Applicants must use human-derived platforms and show that results can be reproduced, and the centers will refine validated tissue models to a level consistent with regulatory qualification. Animal studies and other non-human approaches are excluded.
Timeline
FY 2028: NIH anticipates funding approximately 7 to 11 awards.
January 29, 2027: Application deadline at 5:00 PM local time of the applicant organization.
January 2028: Expected start of funded projects.
The Tech Race
The funding opportunity fits within the broader NIH and FDA new approach methodologies push to replace some animal testing with human-based systems. It positions human microphysiological platforms as candidates for regulatory qualification in infectious-disease research.
U.S. for-profit, nonprofit, and governmental organizations can apply for the awards, so research institutions and companies working on infectious-disease models have a defined deadline to prepare. The projects are not expected to begin until January 2028, so the effect on patients or products is not immediate.
The takeaway
The trajectory to watch is whether human microphysiological platforms move from research tools toward regulatory qualification in infectious disease. The concrete checkpoints are the January 29, 2027 application deadline and the award decisions expected for FY 2028.
What happens next
Applications are due January 29, 2027 at 5:00 PM local time of the applicant organization, and funded projects are expected to begin in January 2028.
Further reading
For broader context on research methods, see Life Sciences coverage.
More information
Read the complete RFA-AI-28-012 full announcement and application guide for eligibility and application details.
Source note: This article includes information reported by Altex.





